INGRAM DOUGLAS S 4

What Happened
Douglas S. Ingram, a director of Relay Therapeutics, was granted a derivative award on June 9, 2026 covering 32,947 shares of the company's common stock. The award was reported at $0.00 (grant of an option/award rather than an open-market purchase or sale). The filing does not show any exercise or sale of shares — this is a grant of rights to acquire shares subject to vesting.

Key Details

• Transaction date and type: June 9, 2026 — Grant/Award (Form 4 code A).
• Quantity and price: 32,947 shares; reported acquisition price $0.00 (derivative award).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnote: The option vests in full on the earlier of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders.
• Filing timeliness: Report lists Period of Report 2026-06-09 and was filed 2026-06-10 — appears to be timely.

Context
This was a stock-based compensation award (an option/derivative grant), not a purchase or sale. Such awards are common for board members and do not by themselves indicate insider buying or selling sentiment. The options have vesting conditions; there is no evidence here of immediate exercise or sale.